Inactive Instrument

Intellipharmaceutics International Inc. Share Price Toronto S.E.

IPCI.H

CA4581733090

Valuation: Intellipharmaceutics International Inc.

Market Cap	14.06L 12.05L 11.29L 10.32L 19.47L 13Cr 19.66L 1.33Cr 51.86L 6.76Cr 52.81L 51.66L 22Cr	P/E 2021	-0.69x	P/E 2022	-0.82x
Enterprise Value	36.49L 31.27L 29.3L 26.76L 50.5L 35Cr 51L 3.46Cr 1.35Cr 18Cr 1.37Cr 1.34Cr 58Cr	EV / Sales 2021	-	EV / Sales 2022	70.4x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Press Releases: Intellipharmaceutics International Inc.

17/20/17

Kahn Swick & Foti, LLC : Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock

More press releases

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	01/04/2007
Christian Akyempon PRN	Corporate Officer/Principal	-	01/02/2014

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	01/09/2004

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	-.--%	-11.11%	-	-	33
ELI LILLY AND COMPANY	-1.06%	+0.65%	+77.42%	+122.82%	1,10000Cr
JOHNSON & JOHNSON	+0.04%	+0.75%	+53.10%	+64.29%	66TCr
ABBVIE INC.	+0.48%	+2.65%	+28.06%	+81.19%	47TCr
ROCHE HOLDING AG	-0.75%	+0.95%	+43.09%	+43.12%	37TCr
NOVARTIS AG	-0.48%	+0.41%	+26.03%	+41.10%	30TCr
ASTRAZENECA PLC	-0.99%	+2.32%	+3.86%	+14.12%	26TCr
AMGEN INC.	-0.36%	+3.99%	+53.31%	+72.49%	24TCr
NOVO NORDISK A/S	+0.24%	+2.89%	-12.21%	-52.34%	21TCr
GILEAD SCIENCES, INC.	+1.38%	+3.72%	+30.33%	+93.56%	18TCr
Average	-0.04%	+3.01%	+33.66%	+53.37%	42.25TCr
Weighted average by Cap.	+0.03%	+2.21%	+45.74%	+71.32%

	2021	2022
Net sales	-	65.73T 56.32T 52.77T 48.21T 90.98T 62.66L 91.87T 6L 2L 31.61L 2L 2L 1.05Cr
Net income	-51.45L -44.09L -41.31L -37.74L -71.22L -49Cr -71.92L -4.87Cr -1.9Cr -25Cr -1.93Cr -1.89Cr -82Cr	-28.92L -24.78L -23.22L -21.21L -40.04L -28Cr -40.43L -2.74Cr -1.07Cr -14Cr -1.09Cr -1.06Cr -46Cr
Net Debt	11.45L 10L 9L 8L 15.85L 11Cr 16.01L 1.08Cr 42.23L 5.51Cr 43.01L 42.07L 18Cr	22.42L 19.21L 18L 16.45L 31.04L 21Cr 31.34L 2.12Cr 82.67L 11Cr 84.19L 82.36L 36Cr

Intellipharmaceutics International Inc. Share Price Toronto S.E.

Stocks

IPCI.H

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Press Releases: Intellipharmaceutics International Inc.

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile